We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug
Read MoreHide Full Article
Pain Therapeutics Inc.’s shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). The company was looking to get Remoxy approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are inadequate. Overall, the company’s shares have declined 56.4%.
The FDA said that Remoxy cannot be approved in its present form. In the CRL, the agency has asked the company to conduct additional studies that are required to gain approval for Remoxy, with label claims on three routes of abuse (injection, inhalation and snorting).
The company had also sought for a label claim against abuse by chewing. In its CRL, the FDA asked company to submit a revised label proposal for the claim.
However, the company confirmed that the FDA did not bring up any safety, efficacy, manufacturing, stability, bioequivalence or any other issue that were raised in the previous CRL. We remind investors that this is the third time that the FDA has issued a CRL for Remoxy.
Pain Therapeutics said that it is currently evaluating the CRL and intends to hold further discussions with the regulatory body. The company said that the additional actions requisitioned by the FDA in the CRL may take approximately a year to conduct and cost the company about $5 million.
The CRL is a huge setback for the company as it is highly dependent on Remoxy for growth and has no approved product in its portfolio. A positive response from the agency would have enabled the company to launch its first drug.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 22% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 54.8% year to date.
Corcept Therapeutics’ earnings estimates for 2016 and 2017 were up 25% and 12.5%, respectively, over the past 60 days. Share price of the company have soared 40.5% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug
The CRL is a huge setback for the company as it is highly dependent on Remoxy for growth and has no approved product in its portfolio. A positive response from the agency would have enabled the company to launch its first drug.
PAIN THERAPEUT Price
PAIN THERAPEUT Price | PAIN THERAPEUT Quote
Pain Therapeutics currently carries a Zacks Rank #2 (Buy). Some other favorably placed stocks in health care sector include Anika Therapeutics Inc (ANIK - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Abbott Laboratories (ABT - Free Report) . All the three stocks sport a a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>